Phase 2Completed

Topical Pentoxifylline Gel on Behcet's Disease Oral Ulcers

Clinical Protocol for Administration of Topical Pentoxifylline Gel on Behcet's Disease Oral Ulcers

Sponsor
Ipekyolu Ilac Ltd. Sti (Industry)
Enrollment
41 enrolled
Conditions
Behçet Disease Affecting Oral Mucosa
Interventions
Pentoxifylline; Colchicine
Ages
adults, older adults
Registry
NCT03888846

Full record on ClinicalTrials.gov

From the registry

Although Behçet's Disease (BD) has no FDA-approved therapies, numerous clinical reports suggest that oral ulcers of BD may resolve when treated with systemic ingested pentoxifylline (PTX). The investigators here propose to investigate the therapeutic potential of PTX dissolved in muco-adherent formulation and directly applied to the oral lesions. This 60 patient proof of concept trial is designed to meet regulatory requirements for safety concerns while at the same time exploring the potential efficacy and clinical utility of this product. The investigators hypothesize that application of topical PTX will accelerate the healing of these lesions in a clinically meaningful way, and further hypothesize that topical PTX can become a valuable adjunct to any other systemic therapy for BD.

Primary outcomes

  • Mean change in the speed of healing of the index oral ulcer
  • Mean change in the total number of oral ulcers
  • Mean change in patient reported outcome pain scores

History

  1. Last registry update

  2. Study completion

  3. Primary completion

  4. Registered

  5. Started